search
Back to results

Filtered Trial for Telmisartan 40mg Non-responder

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
telmisartan+amlodipine
telmisartan
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Essential hypertensive patients who satisfying non-responder criteria
  2. Male or Female
  3. Age 20 years or older
  4. Outpatient

Exclusion Criteria:

  1. Taking four or more anti-hypertensive medications
  2. Secondary hypertension
  3. Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP < 90 mmHg at Visit 3.
  4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias
  5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV
  6. History of myocardial infarction or cardiac surgery within last 6 months
  7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months
  8. History of unstable angina within last 3 months
  9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
  10. History of stroke or transient ischemic attack within last 6 months
  11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy
  12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors
  13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs
  14. Hepatic and/or renal dysfunction
  15. Diagnosed biliary atresia or cholestasis
  16. Hyperkalemia
  17. Dehydration
  18. Sodium deficiency
  19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)
  20. Patients who cannot change to the restricted administration and dosage during study period
  21. Pre-menopausal women who meet any one of the following 1 - 3:

    • Pregnant or possibly pregnant (1)
    • Nursing (2)
    • Desire to become pregnant during study period (3)
  22. Drug or alcohol dependency
  23. Complication of malignant tumour or a disease requiring immunosuppressants
  24. Compliance of < 80% or > 120% during the run-in period
  25. Receiving any investigational therapy within 3 months
  26. Judged to be inappropriate by the investigator or the sub-investigator

Sites / Locations

  • 1235.14.002 Boehringer Ingelheim Investigational Site
  • 1235.14.003 Boehringer Ingelheim Investigational Site
  • 1235.14.005 Boehringer Ingelheim Investigational Site
  • 1235.14.004 Boehringer Ingelheim Investigational Site
  • 1235.14.001 Boehringer Ingelheim Investigational Site

Outcomes

Primary Outcome Measures

Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.

Secondary Outcome Measures

Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Adequate response defined that seated trough diastolic blood pressure was <90 mmHg or decreased from reference baseline by >=10 mmHg at 8 weeks
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Adequate response defined that seated trough systolic blood pressure was <140 mmHg or decreased from reference baseline by >=20 mmHg at 8 weeks (0 percent at baseline)
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
Optimal, normal, high normal blood pressure were defined as follows: Optimal: Systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) < 80 mmHg Normal: SBP >= 120 mmHg or DBP >= 80 mmHg and SBP < 130 mmHg and DBP < 85 mmHg High normal: SBP >= 130 mmHg or DBP >= 85 mmHg and SBP < 140 mmHg and DBP < 90 mmHg
Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

Full Information

First Posted
October 26, 2007
Last Updated
December 12, 2013
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00550953
Brief Title
Filtered Trial for Telmisartan 40mg Non-responder
Official Title
Filtered Trial for Telmisartan 40mg Non-responder
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
314 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
telmisartan+amlodipine
Intervention Type
Drug
Intervention Name(s)
telmisartan
Primary Outcome Measure Information:
Title
Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks
Description
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time Frame
Baseline and 8 Weeks
Secondary Outcome Measure Information:
Title
Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks
Description
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time Frame
Baseline and 8 weeks
Title
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
Description
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time Frame
8 weeks
Title
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
Description
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time Frame
8 weeks
Title
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Adequate response defined that seated trough diastolic blood pressure was <90 mmHg or decreased from reference baseline by >=10 mmHg at 8 weeks
Time Frame
8 weeks
Title
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Adequate response defined that seated trough systolic blood pressure was <140 mmHg or decreased from reference baseline by >=20 mmHg at 8 weeks (0 percent at baseline)
Time Frame
8 weeks
Title
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
Description
Optimal, normal, high normal blood pressure were defined as follows: Optimal: Systolic blood pressure (SBP) < 120 mmHg and diastolic blood pressure (DBP) < 80 mmHg Normal: SBP >= 120 mmHg or DBP >= 80 mmHg and SBP < 130 mmHg and DBP < 85 mmHg High normal: SBP >= 130 mmHg or DBP >= 85 mmHg and SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
8 weeks
Title
Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG
Description
Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Time Frame
First administration of randomised treatment to 24 hours post last dose of randomised treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Essential hypertensive patients who satisfying non-responder criteria Male or Female Age 20 years or older Outpatient Exclusion Criteria: Taking four or more anti-hypertensive medications Secondary hypertension Mean seated diastolic blood pressure (DBP) > 114 mmHg and/or mean seated systolic blood pressure (SBP) > 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP < 90 mmHg at Visit 3. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV History of myocardial infarction or cardiac surgery within last 6 months History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months History of unstable angina within last 3 months Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve History of stroke or transient ischemic attack within last 6 months History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs Hepatic and/or renal dysfunction Diagnosed biliary atresia or cholestasis Hyperkalemia Dehydration Sodium deficiency Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs) Patients who cannot change to the restricted administration and dosage during study period Pre-menopausal women who meet any one of the following 1 - 3: Pregnant or possibly pregnant (1) Nursing (2) Desire to become pregnant during study period (3) Drug or alcohol dependency Complication of malignant tumour or a disease requiring immunosuppressants Compliance of < 80% or > 120% during the run-in period Receiving any investigational therapy within 3 months Judged to be inappropriate by the investigator or the sub-investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1235.14.002 Boehringer Ingelheim Investigational Site
City
Chofu, Tokyo
Country
Japan
Facility Name
1235.14.003 Boehringer Ingelheim Investigational Site
City
Musashino, Tokyo
Country
Japan
Facility Name
1235.14.005 Boehringer Ingelheim Investigational Site
City
Nishi-ku, Hiroshima, Hiroshima
Country
Japan
Facility Name
1235.14.004 Boehringer Ingelheim Investigational Site
City
Osaka, Osaka
Country
Japan
Facility Name
1235.14.001 Boehringer Ingelheim Investigational Site
City
Shinjuku-ku, Tokyo
Country
Japan

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.14_U09-3883.pdf
Description
Related Info

Learn more about this trial

Filtered Trial for Telmisartan 40mg Non-responder

We'll reach out to this number within 24 hrs